Biosimilars (ne)jen v onkologii – dnešní realita i budoucnost
Authors:
R. Demlová 1,2
Authors‘ workplace:
Oddělení klinických hodnocení, Masarykův onkologický ústav, Brno
1; Farmakologický ústav LF MU, Brno
2
Published in:
Klin Onkol 2014; 27(1): 64-66
Category:
Oncology Highlights
Overview
Submitted:
12. 12. 2013
Sources
1. Kresse GB. Biosimilars – science, status, and strategic perspective. Eur J Pharm Biopharm 2009; 72(3): 479–486. doi: 10.1016/j.ejpb.2009.02.014.
2. Egagenerics.com [homepage on the internet]. European Genetic Medicines Association. c2004–2012 EGA. Available from: www.egagenerics.com.
3. Ema.europa.eu [homepage on the internet]. European Medicines Agency. United Kingdom c1995–2014 EMA. Available from: www.ema.europa.eu.
4. Krämer I. Pharmacy and pharmacology of biosimilars. J Endocrinol Invest 2008, 31(5): 479–488.
5. Zuñiga L, Calvo B. Biosimilars approval process. Regul Toxicol Pharmacol 2010; 56(3): 374–377.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2014 Issue 1
Most read in this issue
- Surgical Treatment of Metastases and its Impact on Prognosis in Patients with Metastatic Colorectal Carcinoma
- Enzalutamid (Xtandi®) – nová šance pro pacienty s kastračně refrakterním karcinomem prostaty
- Second Primary Cancers – Causes, Incidence and the Future
- Interaction between p53 and MDM2 in Human Lung Cancer Cells